HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2659 Anti-Haptoglobin Anti-Haptoglobin is an antibody targeting the human haptoglobin (HP). It can be used for immunoblotting after isoelectric focusing to determine Hp alpha subtypes. MW :150 KD. Human IgG1
A2915 Anti-ERG Anti-ERG is a monoclonal IgG1 antibody (mAb) directed against the proto-oncogene ETS-related gene (ERG). It has the potential to treat prostate cancer, Ewing's sarcoma, acute myeloid leukemia, endothelial cancer, and colon cancer. MW: 145.4. Human IgG1
A3171 Anti-ADAM9 (Imgc936) Anti-ADAM9 (Imgc936) is a humanized antibody targeting the ADAM metallopeptidase domain 9 (ADAM9). It is a therapeutic candidate for the treatment of various cancers including non-small cell lung, pancreatic, gastric, breast, ovarian, and colorectal cancer. MW :147.66 KD. Human IgG1
A2660 Seribantumab (Anti-ERBB3 / HER3) Seribantumab (Anti-ERBB3 / HER3) is a fully human IgG2 monoclonal antibody that targets HER3. It inhibits neuregulin 1 (NRG1) fusion-dependent tumorigenesis in vitro and in vivo in breast, lung and ovarian patient-derived cancer models. MW : 143.14 KD. Human IgG2SA
A2916 Anti-GD2 (EMD 273063) Anti-GD2 (EMD 273063) is a humanized immunoglobulin G1 (IgG1) anti-GD2 monoclonal antibody directed against the human pro-inflammatory cytokine interleukin (IL)-2 with potential antineoplastic and immunomodulatory activities. MW: 144.84 KD. Human IgG1
A3172 Cantuzumab (Anti-CanAg) Cantuzumab (Anti-CanAg) humanized monoclonal antibody targeting CanAg. It has broad antitumor efficacy in colon cancer cells. MW :147.02 KD Human IgG1
A2661 Ficlatuzumab (Anti-HGF / SF) Ficlatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD. Human IgG1
A2662 Emibetuzumab (Anti-HGFR / c-Met) Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD. Human IgG4SP
A2663 Anti-IDO2 Anti-IDO2 is a monoclonal antibody targeting Indoleamine 2,3-dioxygenase 2 (IDO2). It exhibits potency that ameliorates arthritis and autoimmune disease. MW :151.06 KD. Human IgG1
A2477 Anti-GPA33 Anti-GPA33 (KRN330) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities. MW: 145.5 KD. Human IgG1
A2664 Rontalizumab (Anti-IFNa1) Rontalizumab (Anti-IFNa1) is a humanized IgG1 monoclonal antibody targets IFN-α. It can be used for the research of systemic lupus erythematosus. MW :150 KD. Human IgG1
A2920 Latozinemab (Anti-Sortilin / SORT1) Latozinemab (anti-Sortilin / SORT1) is a recombinant humanized anti-Sortilin monoclonal antibody. Latozinemab has the potential for progranulin gene (GRN) mutations causative of frontotemporal dementia (FTD) (FTD-GRN) research. MW: 146.28 KD. Human IgG1
A2665 Anrukinzumab (Anti-IL-13) Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD. Human IgG1
A2921 Lemzoparlimab (Anti-CD47) Lemzoparlimab (anti-CD47) is a human monoclonal antibody targeting the human cell surface antigen CD47 with potential phagocytosis-inducing and antineoplastic activities. MW: 145.58 KD. Human IgG4SP
A2666 Anti-IL-13Ra2 / CD213a2 Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD. Human IgG1
A2922 Lilotomab (Anti-TSPAN26 / CD37) Lilotomab (Anti-TSPAN26 / CD37) is a murine immunoglobulin G1 (IgG1) monoclonal antibody directed against the CD37 antigen with potential antineoplastic activity. MW: 145.64 KD. Human IgG1
A2667 Imsidolimab (Anti-IL-1RL2 / IL-36R) Imsidolimab (Anti-IL-1RL2 / IL-36R) is a high-affinity, humanized monoclonal antibody targeting IL-36R. It has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. MW :150 KD. Human IgG4SP
A2923 Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD. Human IgG1
A2668 Etokimab (Anti-IL-33) Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD. Human IgG1
A2924 Lodelcizumab (Anti-PCSK9) Lodelcizumab is a human monoclonal antibody targated against proprotein convertase subtilisin/kexin type 9 (PCSK9) with the potential to be used in research on hypercholesterolemia. MW: 145.66 KD. Human IgG1